{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:28:41Z","timestamp":1774438121432,"version":"3.50.1"},"reference-count":48,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T00:00:00Z","timestamp":1530748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"ANRS (France REcherche Nord&Sud Sida-HIV H\u00e9patites)"},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007110","name":"Schering-Plough","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007110","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002066","name":"GlaxoSmithKline foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Bristol-Myers Squibb Foundation (US)"},{"name":"Merck-Serono"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0199874","type":"journal-article","created":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T13:39:17Z","timestamp":1530797957000},"page":"e0199874","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Evolution of patients\u2019 socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2554-6515","authenticated-orcid":true,"given":"Issifou","family":"Yaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perrine","family":"Roux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabienne","family":"Marcellin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Wittkop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Esterle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Spire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phanie","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boni Armand","family":"Elegbe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel","family":"Piroth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Sogni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Salmon-Ceron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Patrizia","family":"Carrieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the ANRS CO13 HEPAVIH Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2018,7,5]]},"reference":[{"key":"ref1","unstructured":"WHO | Hepatitis C [Internet]. WHO. [cited 2018 Jun 21]. Available from: http:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c<\/ext-link>"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2893.2008.01012.x","article-title":"Expert opinion on the treatment of patients with chronic hepatitis C","volume":"16","author":"S Zeuzem","year":"2009","journal-title":"J Viral Hepat"},{"key":"ref3","first-page":"655","article-title":"Using pegylated interferon and ribavirin to treat patients with chronic hepatitis C","volume":"72","author":"RP Ward","year":"2005","journal-title":"Am Fam Physician"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2036.2006.02748.x","article-title":"Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice","volume":"23","author":"SS Lee","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/j.gastro.2015.01.002","article-title":"Hepatitis C treatment: the data flood goes on-an update from the liver meeting 2014","volume":"148","author":"J-M Pawlotsky","year":"2015","journal-title":"Gastroenterology"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1306218","article-title":"Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection","volume":"370","author":"MS Sulkowski","year":"2014","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/cid\/ciw379","article-title":"All-oral Direct-acting Antiviral Regimens in HIV\/Hepatitis C Virus\u2013coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13\u2013HEPAVIH Cohort","volume":"63","author":"P Sogni","year":"2016","journal-title":"Clin Infect Dis"},{"key":"ref8","article-title":"Efficacy and safety of direct-acting antiviral regimens in HIV\/HCV-co-infected patients\u2013French ANRS CO13 HEPAVIH cohort","author":"L Piroth","journal-title":"J Hepatol"},{"key":"ref9","article-title":"The Hepatitis C Cascade of Care among HIV Infected Patients: A Call to Address Ongoing Barriers to Care","author":"ER Cachay","year":"2014","journal-title":"PLoS ONE"},{"key":"ref10","first-page":"1044","article-title":"Prioritization of high-cost new drugs for HCV: making sustainability ethical","volume":"20","author":"L Crax\u00ec","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref11","unstructured":"Agence France Presse (AFP). H\u00e9patite C: des traitements tr\u00e8s efficaces mais qui profitent \u00e0 tr\u00e8s peu [Internet]. ladepeche.fr. 2016 [cited 2017 Jun 15]. Available from: http:\/\/www.ladepeche.fr\/article\/2016\/01\/12\/2254185-hepatite-traitements-tres-efficaces-profitent-tres-peu.html<\/ext-link>"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2147\/PPA.S30111","article-title":"Patterns and predictors of treatment initiation and completion in patients with chronic hepatitis C virus infection","volume":"6","author":"BT Clark","year":"2012","journal-title":"Patient Prefer Adherence"},{"key":"ref13","unstructured":"Discours de Marisol Touraine\u2014Journ\u00e9e de lutte contre les h\u00e9patites virales [Internet]. Minist\u00e8re Solidar. Sant\u00e9. 2016 [cited 2016 Jun 15]. Available from: http:\/\/solidarites-sante.gouv.fr\/archives\/archives-presse\/archives-discours\/article\/discours-de-marisol-touraine-journee-de-lutte-contre-les-hepatites-virales<\/ext-link>"},{"key":"ref14","first-page":"108","article-title":"RAPPORT DE RECOMMANDATIONS 2016","author":"D Dhumeaux","year":"2016"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/cid\/civ1222","article-title":"How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV\/HCV in the Real World?","volume":"62","author":"S Saeed","year":"2016","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"7846","DOI":"10.3748\/wjg.v19.i44.7846","article-title":"Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care","volume":"19","author":"M Zeremski","year":"2013","journal-title":"World J Gastroenterol WJG"},{"key":"ref17","first-page":"314","article-title":"La co-infection par le virus de l\u2019h\u00e9patite C chez les personnes infect\u00e9es par le VIH: donn\u00e9es de l\u2019enqu\u00eate ANRS-Vespa2","author":"P Roux","year":"2013","journal-title":"Bull Epid\u00e9miologique Hebd"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1472-6963-12-59","article-title":"Engaging HIV-HCV co-infected patients in HCV treatment: the roles played by the prescribing physician and patients\u2019 beliefs (ANRS CO13 HEPAVIH cohort, France)","volume":"12","author":"D Salmon-Ceron","year":"2012","journal-title":"BMC Health Serv Res"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"e103345","DOI":"10.1371\/journal.pone.0103345","article-title":"Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention","volume":"9","author":"L Wiessing","year":"2014","journal-title":"PLOS ONE"},{"issue":"Suppl 1","key":"ref20","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1093\/cid\/cis367","article-title":"HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms","volume":"55","author":"LE Taylor","year":"2012","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/1471-2334-10-303","article-title":"The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): Early findings, 2006\u20132010","volume":"10","author":"M-A Loko","year":"2010","journal-title":"BMC Infect Dis"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/j.1530-0277.2007.00403.x","article-title":"AUDIT-C as a brief screen for alcohol misuse in primary care","volume":"31","author":"KA Bradley","year":"2007","journal-title":"Alcohol Clin Exp Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"RK Sterling","year":"2006","journal-title":"Hepatology"},{"key":"ref24","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004091","article-title":"Liver fibrosis progression and clinical outcomes are intertwined: role of CD4+ T-cell count and NRTI exposure from a large cohort of HIV\/HCV-coinfected patients with detectable HCV-RNA","volume":"95","author":"E Foc\u00e0","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/j.1360-0443.2012.03932.x","article-title":"Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in hepatitis C virus prevalence? Model projections for different epidemic settings","volume":"107","author":"P Vickerman","year":"2012","journal-title":"Addict Abingdon Engl"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.2105\/AJPH.2015.302905","article-title":"Housing Status, Medical Care, and Health Outcomes Among People Living With HIV\/AIDS: A Systematic Review","volume":"106","author":"AA Aidala","year":"2016","journal-title":"Am J Public Health"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/1471-2458-9-270","article-title":"Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting","volume":"9","author":"C Kim","year":"2009","journal-title":"BMC Public Health"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/jvh.12173","article-title":"The new paradigm of hepatitis C therapy: integration of oral therapies into best practices","volume":"20","author":"NH Afdhal","year":"2013","journal-title":"J Viral Hepat"},{"key":"ref29","first-page":"310","article-title":"Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy","volume":"4","author":"SM Lynch","year":"2016","journal-title":"J Clin Transl Hepatol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.3748\/wjg.v13.i17.2436","article-title":"Epidemiology of hepatitis C virus infection","volume":"13","author":"MJ Alter","year":"2007","journal-title":"World J Gastroenterol WJG"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1086\/600304","article-title":"Hepatitis C treatment for injection drug users: a review of the available evidence","volume":"49","author":"M Hellard","year":"2009","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2147\/PPA.S49113","article-title":"Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review","volume":"7","author":"V Mrav\u010d\u00edk","year":"2013","journal-title":"Patient Prefer Adherence"},{"issue":"Suppl 1","key":"ref33","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.drugpo.2014.08.014","article-title":"Prevention, treatment and care of hepatitis C virus infection among people who inject drugs","volume":"26","author":"P Bruggmann","year":"2015","journal-title":"Int J Drug Policy"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1093\/infdis\/jis928","article-title":"Breaking Down the Barriers to Hepatitis C Virus (HCV) Treatment Among Individuals With HCV\/HIV Coinfection: Action Required at the System, Provider, and Patient Levels","volume":"207","author":"J Grebely","year":"2013","journal-title":"J Infect Dis"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/hep.26431","article-title":"Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals","volume":"58","author":"NK Martin","year":"2013","journal-title":"Hepatol Baltim Md"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1093\/cid\/cit326","article-title":"Management of Hepatitis C Virus\/HIV Coinfection Among People Who Use Drugs in the Era of Direct-Acting Antiviral\u2013Based Therapy","volume":"57","author":"LE Taylor","year":"2013","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"ref37","article-title":"Disparities in direct acting antivirals uptake in HIV\u2010hepatitis C co\u2010infected populations in Canada","author":"S Saeed","year":"2017","journal-title":"J Int AIDS Soc"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00042737-200602000-00008","article-title":"Similar compliance and effect of treatment in chronic hepatitis C resulting from intravenous drug use in comparison with other infection causes","volume":"18","author":"G Robaeys","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/00042737-200602000-00003","article-title":"Hepatitis C treatment in drug users: perception versus evidence","volume":"18","author":"D Sylvestre","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.drugpo.2006.12.018","article-title":"The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection","volume":"18","author":"M Hopwood","year":"2007","journal-title":"Int J Drug Policy"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.addbeh.2004.01.006","article-title":"Drug injection cessation among HIV-infected injecting drug users","volume":"29","author":"A-D Bouhnik","year":"2004","journal-title":"Addict Behav"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.neuroscience.2013.04.034","article-title":"Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal","volume":"248","author":"JL Scavone","year":"2013","journal-title":"Neuroscience"},{"key":"ref43","article-title":"How did a Housing First intervention improve health and social outcomes among homeless adults with mental illness in Toronto? Two-year outcomes from a randomised trial","author":"P O\u2019Campo","year":"2016","journal-title":"BMJ Open"},{"key":"ref44","article-title":"Housing First for Adults with Problematic Substance Use","author":"RA Cherner","year":"2017","journal-title":"J Dual Diagn"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/bmb\/ldv004","article-title":"Revolution in hepatitis C antiviral therapy","volume":"113","author":"MD Sadler","year":"2015","journal-title":"Br Med Bull"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1080\/14656566.2016.1182156","article-title":"Prevention and management of treatment failure to new oral hepatitis C drugs","volume":"17","author":"L Ben\u00edtez-Guti\u00e9rrez","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"E97","DOI":"10.9778\/cmajo.20160161","article-title":"Drug therapies for chronic hepatitis C infection: a cost-effectiveness analysis","volume":"5","author":"WWL Wong","year":"2017","journal-title":"CMAJ Open"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/jvh.12411","article-title":"HCV: the best cure possible or the best possible cure?","volume":"22","author":"L Crax\u00ec","year":"2015","journal-title":"J Viral Hepat"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0199874","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T11:01:30Z","timestamp":1540033290000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0199874"}},"subtitle":[],"editor":[{"given":"Yury E.","family":"Khudyakov","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2018,7,5]]},"references-count":48,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,7,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0199874","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,5]]}}}